⚠️ READ FIRST: PNC-27 is an unapproved experimental anticancer peptide that the FDA has explicitly WARNED against, products have been found bacterially contaminated, and there is NO verified human clinical trial data. It must never be treated as a usable cancer therapy.
PNC-27 Prices
8 vendors · 4 with an issuer-verified COA · lowest 10mg from $58.50 · checked
Where to buy PNC-27: 8 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $58.50 | Buy PNC-27 from Novaglo Research | |
| 5-test panelVerified COAFreedom Diagnostics · Tested Jul 13, 2026 | $59.99 | Buy PNC-27 from Modern Research Peptides |
| $82.50 | Buy PNC-27 from Atomik Labz | |
| 3-test panelVerified COAFreedom Diagnostics | $93.60 | Buy PNC-27 from Nationwide Peptides |
| 3-test panelVerified COABioRegen · Tested May 14, 2026 | $99.0010mg packageChecked today | Buy PNC-27 from NextGenPeps |
| 3-test panelVerified COAKovera Labs · Tested Aug 13, 2026 | $112.002 × 5mg packages · 10mg totalChecked today | Buy PNC-27 from Pure Peptides |
| $164.79 | Buy PNC-27 from Cenexa Labs | |
| $251.97 | Buy PNC-27 from BioLongevity Labs |
Tracked every day
PNC-27 listing prices, tracked daily
The five cheapest in-stock package prices for PNC-27 on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$39.99
- 2nd cheapest$56.00
- 3rd cheapest$65.00
- 4th cheapest$99.00
- 5th cheapest$104.00
Vendors most often in the cheapest five
- Nationwide Peptides41 days$104.00-17.5%
- Modern Research Peptides16 days$39.990.0%
- NextGenPeps16 days$99.000.0%
- Cenexa Labs6 days$205.99last seen Oct 6, 20260.0%
- BioLongevity Labs6 days$279.97last seen Sep 30, 20260.0%
- Atomik Labz5 days$110.00last seen Sep 29, 20260.0%
- Novaglo Research4 days$65.000.0%
- Pure Peptides3 days$56.000.0%
Current market data
PNC-27 Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for PNC-27 is $58.50 from Novaglo Research. The median across vendors is $96.30.
- Lowest 10mg cost
- $58.50Novaglo Research
- Median 10mg cost
- $96.30One normalized offer per vendor
- Lowest package total
- $29.99Modern Research Peptides · package size may differ
- Public COA coverage
- 100%8 of 8 vendors
What the market shows
PeptidePrices found 9 in-stock listings from 8 vendors, checked through Oct 10, 2026. The lowest 10mg cost is 39% below the vendor median of $96.30; 4 vendors (50%) fall below that median. 8 of 8 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is PNC-27? Research, safety, and status
PNC-27 is an experimental anticancer peptide designed in 2000 (Pincus & Michl, SUNY Downstate) by combining the HDM-2 (MDM2)-binding region of the tumor-suppressor p53 with a membrane-penetrating peptide. In cell culture it appears to selectively kill cancer cells by forming pores in their membranes.
This is the one profile where the warning comes before the science. The FDA has issued explicit warnings about PNC-27 products, including documented bacterial contamination, and there is no verified human safety or efficacy data of any kind. Nothing here is medical advice, and PNC-27 is not a treatment, it is an unproven, FDA-flagged research chemical.
Key research takeaways
It is a 32-amino-acid chimeric peptide: a p53/HDM-2-binding domain fused to a membrane-penetrating sequence (penetratin). In cell studies it selectively lyses cancer cells that display HDM-2 on their membrane, reportedly sparing normal cells.
All efficacy evidence is in vitro/preclinical. Secondary-source claims of human use exist but have no verifiable trial registrations or peer-reviewed results.
Anyone facing cancer should consult a qualified oncologist and rely on FDA-approved treatments, this profile is for research context only.
PNC-27 at a glance
PeptidePrices safety rating
2/10 · Not FDA-approved (FDA warning issued)
Mechanism
Synthetic peptide containing p53 activation domain fused to penetratin cell-penetrating sequence; selectively inserts into membranes of cancer cells (which overexpress HDM2); induces apoptosis in cancer cells while leaving normal cells unharmed.
Research areas
Anticancer research; selective cancer cell apoptosis; solid tumors (pancreatic, breast, leukemia in animal studies); research compound with promising selective toxicity profile.
Regulatory / research status
Research / preclinical only
Half-life
Not established in humans.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Limited human data. Animal studies show selective cancer cell killing with minimal normal cell toxicity. Long-term safety profile not established.
⚠️ FDA has explicitly warned against PNC-27 products; documented bacterial contamination (Variovorax paradoxus) in marketed material; ZERO verified human trials; marketed with unsubstantiated cancer-cure claims. Experimental only, never a usable cancer therapy. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- ⚠️ PNC-27 is an unapproved experimental anticancer peptide that the FDA has explicitly warned against, with documented bacterial contamination in marketed products and NO verified human clinical trial data.
- It is a 32-amino-acid chimeric peptide (a p53/HDM-2-binding domain fused to a membrane-penetrating sequence) studied in cell lines for selectively lysing cancer cells via membrane HDM-2.
- All efficacy data is in vitro/preclinical; secondary-source human 'trial' claims have no verifiable NCT numbers or peer-reviewed results.
- This must be treated as experimental, not a usable cancer therapy, anyone facing cancer should consult an oncologist and rely on FDA-approved treatments.
Selected references
Related pages